Anti-MSLN uCAR-like NK cells, endowed with tumor-penetrating capabilities, are able to infiltrate tumor tissues and induce tumor regression, providing a solid foundation for the clinical application of immunotherapies targeting MSLN-positive solid tumors. The gene discussed is MSLN; the disease is neoplasm.